pyrroles has been researched along with Epithelial Ovarian Cancer in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, Y; Hu, W; Lou, G; Pan, M; Peng, J; Shi, H; Sun, R; Wang, L; Wang, Q; Wu, X; Xia, L; Zhang, Y; Zhou, Q; Zhou, X; Zhu, J | 1 |
| Brickman, D; Cristea, M; Fleming, GF; Fong, A; French, D; Hamilton, E; Moore, K; O'Cearbhaill, R; O'Malley, DM; Rossi, M; Tariq, B | 1 |
| Brady, W; Brown, J; Chan, JK; Gershenson, DM; Kim, JH; Monk, BJ; Rose, PG; Secord, AA; Shahin, MS; Walker, JL | 1 |
| Gao, L; Gao, Y; Li, J; Shan, N; Wang, Y; Xu, F; Yi, Z; Yu, X; Zhao, C | 1 |
| Alsina-Sanchis, E; Casanovas, O; Figueras, A; Graupera, M; Lahiguera, Á; Vidal, A; Villanueva, A; Viñals, F | 1 |
| Amaravadi, RK; Anglesio, MS; DeVorkin, L; Hattersley, M; Huntsman, DG; Kim, P; Levi, SM; Lum, JJ; Ries, J; Spowart, J; Tinker, AV; Winkler, JD | 1 |
| Colon-Otero, G; Copland, JA; Kennedy, GT; Kennedy, WP; Marlow, LA; Santoso, JT; Vishnu, P; Wu, KJ | 1 |
3 trial(s) available for pyrroles and Epithelial Ovarian Cancer
| Article | Year |
|---|---|
Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Carcinoma, Ovarian Epithelial; Female; Humans; Indoles; Middle Aged; Pyrroles | 2022 |
Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study.
Topics: Adult; Aged; Aged, 80 and over; Benzodiazepines; Carcinoma, Ovarian Epithelial; Dipeptidases; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Immunoconjugates; Middle Aged; Molecular Targeted Therapy; Ovarian Neoplasms; Pyrroles | 2020 |
A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254).
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Ovarian Epithelial; Female; Humans; Indoles; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Pyrroles; Sunitinib; Young Adult | 2018 |
4 other study(ies) available for pyrroles and Epithelial Ovarian Cancer
| Article | Year |
|---|---|
LY2109761 enhances cisplatin antitumor activity in ovarian cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Mice, Inbred ICR; Mice, SCID; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazoles; Pyrroles; Receptor, Transforming Growth Factor-beta Type I; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Signal Transduction; Smad2 Protein; Time Factors; Transforming Growth Factor beta; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
The TGFβ pathway stimulates ovarian cancer cell proliferation by increasing IGF1R levels.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Ovarian Epithelial; Cell Proliferation; Female; Heterografts; Humans; Mice; Mice, Nude; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Pyrazoles; Pyrroles; Random Allocation; Receptor, IGF Type 1; Receptors, Somatomedin; Signal Transduction; Transforming Growth Factor beta | 2016 |
Autophagy Inhibition Enhances Sunitinib Efficacy in Clear Cell Ovarian Carcinoma.
Topics: Adenocarcinoma, Clear Cell; Aminoquinolines; Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Female; Humans; Indoles; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Polyamines; Pyrroles; Sunitinib; Xenograft Model Antitumor Assays | 2017 |
RhoB mediates antitumor synergy of combined ixabepilone and sunitinib in human ovarian serous cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cell Growth Processes; Cell Line, Tumor; Cystadenocarcinoma, Serous; Dose-Response Relationship, Drug; Drug Synergism; Epothilones; Female; Humans; Indoles; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Pyrroles; rhoB GTP-Binding Protein; Sunitinib; Up-Regulation | 2012 |